Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins and Other Symptomatic Venous Disorders
Clinical medical necessity and coding guidance for sclerotherapy (liquid or foam) and chemical endovenous ablation (cyanoacrylate) for symptomatic varicose veins and other venous disorders for Fidelis Care/Centene-affiliated health plans.
Updated reflux thresholds from ≥ 500 milliseconds to > 500 milliseconds and perforating vein diameter from ≥ 3.5 mm to > 3.5 mm in multiple criteria.
Added cyanoacrylate (VenaSeal) codes (36482, 36483) to codes that support medical necessity and clarified cyanoacrylate is used for endovenous ablation not sclerotherapy.
Added requirement for documentation of symptomatic CEAP class C2s or greater as an eligibility criterion.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.